Memo Therapeutics (spinoff from ETH Zurich) is using its proprietary MemoMABé technology to develop a therapeutic antibody pipeline targeting infectious diseases, cancer and immune mediated inflammatory diseases (IMID).
Memo Therapeutics AG
Management
Technology
Deals/Partnering
Research Pipeline
Funding
BioStartup's Score
0 / 50
KEY DETAILS
Websitehttp://memomab.com
Disease Focus
STOCK CODENon Listed
AddressieLab ETH Honggerberg, HPL DOtto-Stern-Weg 78093ZurichSwitzerland
ieLab ETH Honggerberg, HPL DOtto-Stern-Weg 78093
Zurich
Switzerland
Contact Number
[atom_linkedin linkedin_option=”CompanyInsider” linkedin_id=”https://www.linkedin.com/company/memo-therapeutics-ag” connections=”true” suffix=””]
Memo Therapeutics proprietary MemoMABé platform drives the companys proprietary antibody and target discovery, and is made available to partners and clients in the industry as well as for selected projects with academia.
In July 2015, Memo Therapeutics raised 2.3 Mn Swiss Francs in a series A round, from investors including EVA Basel, Redalpine Venture Partners and Zu?rcher Kantonalbank.